PRIMARY OBJECTIVES:
I. To measure the relative changes in cell cycle-related genetic signature of the tumor microenvironment post administration of neoadjuvant nivolumab in children and young adults with recurrent or progressive HGG when compared to a cohort of archived non-treated recurrent pediatric HGG samples.
II. To characterize the safety and tolerability of neoadjuvant nivolumab followed by adjuvant nivolumab in children and young adults with recurrent or progressive HGG.
SECONDARY OBJECTIVES:
I. To determine the 6 month and 12 month overall survival (OS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
II. To determine the 6 month and 12 month progression-free survival (PFS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
EXPLORATORY OBJECTIVES:
I. To measure relative changes in interferon gamma associated genetic signature within the tumor microenvironment post administration of neoadjuvant nivolumab in children and young adults with recurrent or progressive HGG compared to archived non-treated recurrent pediatric HGG samples.
II. To explore the correlation of interferon-gamma-associated genetic signature, cell cycle-related genetic signature and infiltrating T lymphocyte (TIL) density and clonality with clinical responses.
III. To measure TIL density post administration of neoadjuvant nivolumab in children and young adults with recurrent or progressive HGG.
IV. To estimate the objective response rate (ORR) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
V. To evaluate the association between advanced MRI parameters (ADC on DWI, rCBV on dynamic susceptibility contrast (DSC) perfusion MRI, pre-contrast T1 shortening on T1-weighed images, and/or MTRasym on pH-Weighted Amine CEST-EPI) and tumor and peripheral blood immune responses.
VI. To measure relative change in peripheral T-cell response and post administration of neo-adjuvant nivolumab in children and young adults with recurrent or progressive HGG.
VII. To measure PD-1 and PDL-1 expression by immunohistochemistry for children and young adults with recurrent or progressive HGG post neoadjuvant nivolumab and evaluate the differences between the treatment cohort and archived non-treated recurrent pediatric HGG samples.
VIII. To explore the correlation of tumor mutational load with clinical response for children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
IX. To assess Quality of Life (QOL) and cognitive measures in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
X. To assess patient and/or proxy satisfaction with study participation via patient-reported outcome (PRO) measures in the context of race ethnicity and other health related social risks.
XI. To assess on therapy toxicity in the context of race, ethnicity and other health related social risks.
OUTLINE: Neoadjuvant nivolumab followed by adjuvant nivolumab evaluation.
NEOADJUVANT TREATMENT: Participants will receive a single infusion of nivolumab of 3 mg/kg 14± 5 days prior to surgery. When scheduling, please keep in mind that the two pre-surgical plasma samples (day of neoadjuvant dose and day of surgery) should be drawn greater than 10 days apart.
Tumor samples will be obtained at time of surgery. The tissue from this surgery (fresh, frozen and FFPE) and the archived tissue (FFPE) from the most recent surgery prior to registration revealing HGG will be processed so as to best achieve the primary, secondary and exploratory objectives.
ADJUVANT TREATMENT: Infusion Cycle #1 should begin as soon as participant has recovered from surgery and has been tapered off of steroids. A maximum dexamethasone dose of 0.1 mg/kg/day is allowed, but preferably have been discontinued (inhaled or topical use of steroids is allowed).
Maintenance Cycle 1+ Day 1 \& 15: Participants will receive nivolumab (3mg/kg) IV every 2 weeks until progression or development of unacceptable toxicities or withdrawal. Blood samples will be obtained as pharmacodynamic markers throughout the study (Day 1 of every other cycle). Dose interruptions and symptomatic management will occur based upon preset adverse event determination.
After completion of study treatment, patients are followed up at 30 days and then every 2 months for up to 5 years.
Inclusion Criteria:
1. Participants with recurrent or progressive high-grade gliomas (HGG) (World Health
Organization (WHO) grade III or grade IV) who are candidates for surgical tumor
debulking will be enrolled in this trial
2. All assessments are to occur within 14 days of registration except where otherwise
noted. The participant and their legal parent/guardian must be thoroughly informed
about all aspects of the study, including the study visit schedule and required
evaluations and all regulatory requirements for informed consent. The written informed
consent must be obtained from the participant and legal parent/guardian prior to
enrollment
3. Have a history of previously treated histologically confirmed World Health
Organization grade III or IV HGG. Previous first line therapy with radiation and/or
chemotherapy
4. Have evidence of recurrence or progression of disease by MRI scan
5. Participants must be adequate medical candidates for surgical resection. The intent of
surgical resection is to allow both cytoreduction and tumor debulking as part of
standard of care, and also collect a minimum of 100 mg of tumor tissue for the study
tissue endpoints
6. A primary goal of surgery must be cytoreduction, and not solely on diagnostic biopsy
7. Age: Participants must be > 6 months and < 25 years of age at time of enrollment
8. Karnofsky >= 50 for participants > 16 years of age and Lansky >= 50 for participants
=< 16 years of age. Participants who are unable to walk because of paralysis, but who
are up in a wheelchair, will be considered ambulatory for the purpose of assessing the
performance score
9. Patients with neurological deficits should have deficits that are stable for a minimum
of 1 week prior to enrollment (on stable or tapering dosing of steroids). A baseline
detailed neurological exam should clearly document the neurologic status of the
patient at the time of enrollment on the study.
10. Prior Therapy: Participants must have fully recovered from the acute toxic effects of
all prior anti-cancer therapy and must meet the following minimum duration from prior
anti-cancer directed therapy prior to enrollment. If after the required timeframe, the
defined eligibility criteria are met, e.g. blood count criteria, the patient is
considered to have recovered adequately
- Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive.
At least 21 days after the last dose of cytotoxic or myelosuppressive
chemotherapy (42 days if prior nitrosourea)
- An interval of at least 12 weeks from the completion of radiation therapy to
registration unless there is unequivocal histologic confirmation of tumor
progression
- Hematopoietic growth factors: At least 14 days after the last dose of a
long-acting growth factor (e.g. pegfilgrastim) or 7 days for short acting growth
factor. For agents that have known adverse events occurring beyond 7 days after
administration, this period must be extended beyond the time during which adverse
events (AEs) are known to occur. The duration of this interval must be discussed
with the study chair.
- Had their last dose of biologic (anti-neoplastic agent) ≥7 days prior to
study registration, or beyond the time during which AEs are known to occur.
- Anti-cancer agents not known to be myelosuppressive (e.g. not associated with
reduced platelet or absolute neutrophil count [ANC] counts): At least 7 days
after the last dose of agent
- Interleukins, interferons and cytokines (other than hematopoietic growth
factors): >= 21 days after the completion of interleukins, interferon or
cytokines (other than hematopoietic growth factors)
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody,
and toxicity related to prior antibody therapy must be recovered to grade =< 1
- An interval of at least 12 weeks from prior exposure to PD-1 or PD-L1 inhibitors.
- Stem cell infusion (with or without total-body irradiation (TBI)):
- Autologous stem cell infusion including boost infusion: >= 42 days
11. Participants must be willing to forego cytotoxic anti-tumor therapies except
study-defined therapy while being treated on study
12. Organ Function Requirements:
- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
- Platelet count >= 100,000/mm^3
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows:
- Age: Maximum Serum Creatinine (mg/dL)
- 6 months to < 3 years: 0.6 (male and female)
- 3 to < 6 years: 0.8 (male and female)
- 6 to < 10 years: 1 (male and female)
- 10 to < 13 years: 1.2 (male and female)
- 13 to < 16 years: 1.5 (male), 1.4 (female)
- >= 16 years: 1.7 (male), 1.4 (female)
- Bilirubin (sum of conjugated and unconjugated) =< 1.5 x upper limit of normal
(ULN) for age (except participants with Gilbert syndrome who must have a total
bilirubin level of < 3.0
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN
- Serum albumin >= 2
13. Pregnancy: The effects of nivolumab on the developing human fetus are unknown. For
this reason women of child-bearing potential must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, for
the duration of study participation and 5 months after completion of therapy. Should a
woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician immediately.
14. MRI within 28 days prior to registration.
Exclusion Criteria:
1. Current or planned participation in a study of an investigational agent or using an
investigational device.
2. Has a diagnosis of immunodeficiency.
3. Has tumor primarily localized to the brainstem or spinal cord.
4. Has presence of diffuse leptomeningeal disease or or disseminated/multi-focal disease,
or extracranial disease.
5. Has received systemic immunosuppressive treatments (such as methotrexate, chloroquine,
azathioprine, etc.), aside from anti-neoplastic chemotherapy or systemic
corticosteroids within six months of registration.
6. Participants with a concurrent condition requiring systemic treatment with either
corticosteroids (> 0.25 mg/kg daily prednisone equivalent) or other immunosuppressive
medications within 14 days of start of study treatment. Inhaled or topical steroids,
and adrenal replacement steroid doses > 0.25 mg/kg daily prednisone equivalent, are
permitted in the absence of active autoimmune disease.
7. Unable to taper steroids due to ongoing mass effect; a maximum dexamethasone dose of
0.1 mg/kg/day is allowed (4mg maximum), but preferably have been discontinued (inhaled
or topical use of steroids is allowed).
8. Has a known history of active TB (Bacillus tuberculosis).
9. Has a known additional malignancy that is progressing or requires active treatment
within 3 years of registration. Exceptions include basal cell carcinoma of the skin,
squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone
potentially curative therapy.
10. Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.
11. Has known history of, or any evidence of active non-infectious pneumonitis.
12. Has an active infection requiring systemic therapy.
13. Has a known hypersensitivity to any of the study therapy products.
14. Has a known history of positive test for human immunodeficiency virus (HIV) or known
acquired immunodeficiency syndrome (AIDS).
- NOTE: Testing for HIV must be performed at sites where mandated locally
15. Any prior positive test result for hepatitis B virus or hepatitis C virus indicating
presence of virus, e.g., hepatitis B surface antigen (HBsAg, Australia antigen)
positive, or hepatitis C antibody (anti-HCV) positive (except if HCV-ribonucleic acid
(RNA) negative).
16. Participants who have had prior allogenic hematopoietic stem cell transplant (HSCT).
17. Any serious or uncontrolled medical disorder that, in the opinion of the investigator
may increase the risk associated with study participation or study drug
administration, impair the ability of the participant to receive protocol therapy or
interfere with interpretation of study results.
